Source:http://linkedlifedata.com/resource/pubmed/id/21186965
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-12-28
|
| pubmed:databankReference | |
| pubmed:abstractText |
Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients. Here, we investigated differences between age- and gender-normed body mass index-standardized z scores at baseline and after 8 weeks of open-label, flexible-dose risperidone treatment (mean dose: 1.70? mg/day) in 32 youths with pervasive developmental disorder (mean age?=?8.74, range?=?5-16 years) in relation to -759C/T 5-hydroxytryptamine 2C receptor (HTR2C) promoter and rs1414334 HTR2C intragenic C/G alleles, along with gender, age, and risperidone dose, using repeated measures analyses of variance. Carriers of the HTR2C promoter T allele gained an average of 0.043?±?0.017 body mass index-standardized z scores (1.84?±?1.51? kg) versus 0.64?±?0.35 z (3.23?±?1.47? kg) for non-T-allele carriers (p?<?0.001). Presence of the rs1414334 C allele played no significant role. Further, weight gain appeared to be associated with younger age and higher doses of risperidone. The current preliminary findings suggest that the variant T allele of the -759C/T HTR2C promoter polymorphism is protective against risperidone-induced weight gain. Younger children and those treated with higher doses of risperidone may be at higher risk for weight gain.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1557-8992
|
| pubmed:author |
pubmed-author:AndersonGeorge MGM,
pubmed-author:BuitelaarJan KJK,
pubmed-author:FrankeBarbaraB,
pubmed-author:HoekstraPieter JPJ,
pubmed-author:LahuisBertine EBE,
pubmed-author:MinderaaRuud BRB,
pubmed-author:MulderErik JEJ,
pubmed-author:MulderHansH,
pubmed-author:ScahillLawrenceL,
pubmed-author:TroostPieter WPW
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
473-7
|
| pubmed:meshHeading |
pubmed-meshheading:21186965-Adolescent,
pubmed-meshheading:21186965-Age Factors,
pubmed-meshheading:21186965-Analysis of Variance,
pubmed-meshheading:21186965-Antipsychotic Agents,
pubmed-meshheading:21186965-Body Mass Index,
pubmed-meshheading:21186965-Child,
pubmed-meshheading:21186965-Child, Preschool,
pubmed-meshheading:21186965-Child Development Disorders, Pervasive,
pubmed-meshheading:21186965-Dose-Response Relationship, Drug,
pubmed-meshheading:21186965-Female,
pubmed-meshheading:21186965-Humans,
pubmed-meshheading:21186965-Male,
pubmed-meshheading:21186965-Polymorphism, Genetic,
pubmed-meshheading:21186965-Promoter Regions, Genetic,
pubmed-meshheading:21186965-Prospective Studies,
pubmed-meshheading:21186965-Receptor, Serotonin, 5-HT2C,
pubmed-meshheading:21186965-Risk Factors,
pubmed-meshheading:21186965-Risperidone,
pubmed-meshheading:21186965-Sex Factors,
pubmed-meshheading:21186965-Weight Gain
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.
|
| pubmed:affiliation |
Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. p.hoekstra@accare.nl
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|